NKTX Nkarta, Inc.
$2.91▲ +3.56%
Healthcare
Other
After hours
$2.96▲ +1.72%
Sep 11, 7:30 PM ET
Volume 486.8K
Avg Volume (10D) 648.6K
Key Metrics & Fundamentals
Market Cap
$208.43M
P/E Ratio
–
Div Yield
–%
52W Range
1.70 - 3.72
% vs 50 MA
11.20%
% vs 200 MA
18.26%
RSI-14
57.4
MACD Histogram
+0.0300
Beta (1Y vs SPY)
2.03
Free Cash Flow
-$24.41M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$40.40M
COGS
–
Operating Exp
$43.13M
Operating Income
-$43.13M
EBIT
-$43.13M
Pretax Income
-$40.37M
Net Income
-$40.37M
EPS (Diluted)
-0.54
Price & Volume History
Loading chart…
Recent News
Nkarta to Participate in September Investor Conferences
GlobeNewswire · Sep 10, 2026 11:00 AM
Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026
GlobeNewswire · Sep 8, 2026 11:00 AM
Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights
GlobeNewswire · Aug 10, 2026 8:24 PM
Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development
GlobeNewswire · Jul 23, 2026 5:30 AM
Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
GlobeNewswire · Jun 26, 2026 12:45 PM
TD Cowen Initiates Nkarta at Buy
MT Newswires · Jun 23, 2026 10:05 AM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See NKTX's money flow as a full page
Social Sentiment
No Reddit posts found for NKTX.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.